Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Immunotherapy in Pancreatic Cancer
NCT03114631Phase 2Completed
- Sponsor
- Republican Research and Practical Center for Epidemiology and Microbiology
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of TLP0-001 in pancreatic cancer (PC) (3 arms), sponsored by Republican Research and Practical Center for Epidemiology and Microbiology. Primary endpoints: Number of Participants with PR or CR at 1 year and Number of Participants Who Survived at 1 Year. Started Jan 2017; status: completed.
02
Drugs
TLP0-001
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03114631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114631.